Research map: Dual bispecific protein engager–armed T cells targeting BCMA and B7-H3 overcome antigen heterogeneity in multiple myeloma

Back to the article

Papers in this map

  1. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma · S. Vincent Rajkumar · 2014 · 5044 citations · Cited by this paper
  2. 2-deoxy-d-ribose: A multifaceted player at the crossroads of cancer metabolism · 2026 · Related
  3. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results · Alexander M. Lesokhin · 2023 · 640 citations · Cited by this paper
  4. Activity-dependent metabolic vulnerability in the APPPS1 Alzheimer’s disease mouse model during isoflurane anesthesia · 2026 · Related
  5. Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity · Elise Alspach · 2018 · 610 citations · Cited by this paper
  6. Tailoring pH-responsive charge-conversional interfaces in ionizable lipid-based nanoliposomes for synchronized co-delivery and synergistic therapy of triple-negative breast cancer · 2026 · Related
  7. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma · Mehmet Samur · 2021 · 426 citations · Cited by this paper
  8. Preserved motor function and prolonged sensory local anesthesia with novel PLGA microparticles co-encapsulating lidocaine and capsaicin · 2026 · Related
  9. A Single Peptide-Major Histocompatibility Complex Ligand Triggers Digital Cytokine Secretion in CD4+ T Cells · Jun Huang · 2013 · 418 citations · Cited by this paper
  10. Iron–quercetin complex induces ex vivo proteomic remodeling in circulating proangiogenic cells derived from human peripheral blood mononuclear cells · 2026 · Related
  11. T Cell Dysfunction and Exhaustion in Cancer · Zhen Zhang · 2020 · 398 citations · Cited by this paper
  12. Acetonic extract of Saskatoon berry attenuates amyloid-associated neurotoxicity in cellular and Drosophila melanogaster Alzheimer’s disease models · 2026 · Related
  13. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma · Holly Lee · 2023 · 356 citations · Cited by this paper
  14. Design of sunflower trypsin inhibitor 1 derived probes targeting the LDLR and evaluation of their brain delivery · 2026 · Related
  15. LAG-3 as the third checkpoint inhibitor · Vaishali Aggarwal · 2023 · 347 citations · Cited by this paper
  16. The chalcone derivative DN-053 attenuates renal fibrosis and inhibits p38 MAPK and STAT3 signaling in renal fibroblasts · 2026 · Related
  17. Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex · Alexis M. Kalergis · 2001 · 331 citations · Cited by this paper
  18. Characterization of anti-CD3 antibodies in clinically available bispecific T cell engagers · 2025 · Related
  19. Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+ T Cells · Keisuke Watanabe · 2014 · 294 citations · Cited by this paper
  20. Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells · Joseph F. Grosso · 2009 · 279 citations · Cited by this paper
  21. Granzyme B: pro-apoptotic, antiviral and antitumor functions · Joseph A. Trapani · 2003 · 268 citations · Cited by this paper
  22. IFN-γ: A cytokine at the right time, is in the right place · J. D. Burke · 2019 · 262 citations · Cited by this paper
  23. Receptor Signaling Clusters in the Immune Synapse · Michael Loran Dustin · 2012 · 248 citations · Cited by this paper
  24. Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma · Zhi‐Zhang Yang · 2017 · 224 citations · Cited by this paper
  25. Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class · Klaus Brischwein · 2007 · 190 citations · Cited by this paper
  26. Crystal structure of the human T cell receptor CD3εγ heterodimer complexed to the therapeutic mAb OKT3 · Lars Kjer‐Nielsen · 2004 · 181 citations · Cited by this paper
  27. Anti‐cancer therapy with TNF α and IFN γ: A comprehensive review · Jing Shen · 2018 · 172 citations · Cited by this paper
  28. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells · Ralf Lutterbuese · 2010 · 169 citations · Cited by this paper
  29. The landscape of T cell antigens for cancer immunotherapy · Aviyah Peri · 2023 · 145 citations · Cited by this paper
  30. CD4+ T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B · Yuejiao Dong · 2019 · 142 citations · Cited by this paper
  31. The current state and future of T-cell exhaustion research · Edward M. Jenkins · 2023 · 138 citations · Cited by this paper
  32. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study · Ajai Chari · 2025 · 110 citations · Cited by this paper
  33. Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody · Karin Staflin · 2020 · 108 citations · Cited by this paper
  34. The synapse and cytolytic machinery of cytotoxic T cells · Misty Rayna Jenkins · 2010 · 102 citations · Cited by this paper
  35. FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma · Poornima Sharma · 2022 · 99 citations · Cited by this paper
  36. B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3 · Liang Lin · 2018 · 78 citations · Cited by this paper
  37. Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade · Mikaël Roussel · 2021 · 68 citations · Cited by this paper
  38. From TCR fundamental research to innovative chimeric antigen receptor design · Susana Minguet · 2024 · 51 citations · Cited by this paper
  39. FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma · Kavita Natrajan · 2024 · 50 citations · Cited by this paper

Source: OpenAlex (CC0)